Cargando…

Immune desert in MMR-deficient tumors predicts poor responsiveness of immune checkpoint inhibition

BACKGROUND: Although many efforts have been devoted to identify biomarkers to predict the responsiveness of immune checkpoint inhibitors, including expression of programmed death-ligand 1 (PD-L1) and major histocompatibility complex (MHC) I, microsatellite instability (MSI), mismatch repair (MMR) de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Guoxing, Lu, Yingsi, Yang, Zheng, Chen, Hong, Liang, Qian, Zhu, Qingqing, Li, Yan, Xiao, Xing, He, Zhuzhen, Zhu, Yifan, Li, Bo, Huang, Leilei, Dong, Nan, Hu, Shuang, Pan, Yihang, Zhang, Changhua, Zhu, Chengming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175608/ https://www.ncbi.nlm.nih.gov/pubmed/37187745 http://dx.doi.org/10.3389/fimmu.2023.1142862

Ejemplares similares

Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
por: Marmorino, Federica, et al.
Publicado: (2020)

Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer
por: Bui, Quang Loc, et al.
Publicado: (2022)

Case Report: Complete Response to Antiangiogenesis and Immune Checkpoint Blockade in an Unresectable MMR-Deficient Leiomyosarcoma Harboring Biallelic Loss of PTEN
por: Guo, Xi, et al.
Publicado: (2022)

Rapid generation and selection of Cas9-engineering TRP53 R172P mice that do not have off-target effects
por: Zheng, Guoxing, et al.
Publicado: (2019)

Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors
por: Salewski, Inken, et al.
Publicado: (2021)

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
por: Fucà, Giovanni, et al.
Publicado: (2022)

Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors
por: Gantzer, Justine, et al.
Publicado: (2022)

Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
por: Nasca, Vincenzo, et al.
Publicado: (2023)

Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
por: Sahin, Ibrahim Halil, et al.
Publicado: (2019)

Immune Checkpoints in Viral Infections
por: Cai, Huiming, et al.
Publicado: (2020)

Challenges presented by complete response to immune checkpoint blockade in patients with dMMR colorectal cancer: A case report
por: Smith, Henry G., et al.
Publicado: (2023)

The Glycosylation of Immune Checkpoints and Their Applications in Oncology
por: Zheng, Linlin, et al.
Publicado: (2022)

Immune response to second dose of MMR vaccine in Indian children
por: Gomber, Sunil, et al.
Publicado: (2011)

Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer
por: Su, Alan, et al.
Publicado: (2023)

Increasing cure rates of solid tumors by immune checkpoint inhibitors
por: Ma, Weijie, et al.
Publicado: (2023)

Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma
por: Zeng, Zhu, et al.
Publicado: (2020)

Chromothripsis is correlated with reduced cytotoxic immune infiltration and diminished responsiveness to checkpoint blockade immunotherapy
por: Chu, Han, et al.
Publicado: (2023)

Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H)
por: Liao, Ying, et al.
Publicado: (2022)

Targeting immune checkpoints in malignant glioma
por: Zhang, Xuhao, et al.
Publicado: (2016)

Application of a fast and cost-effective ‘three-in-one’ MMR ELISA as a tool for surveying anti-MMR humoral immunity: the Hungarian experience
por: Böröcz, K., et al.
Publicado: (2020)

ENPEP as a potential predictor of immune checkpoint inhibitor efficacy
por: Wang, Aoyun, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors Related to Cardiotoxicity
por: Chen, Ru, et al.
Publicado: (2022)

Immune checkpoint therapy in liver cancer
por: Xu, Feng, et al.
Publicado: (2018)

BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
por: Fu, Yu, et al.
Publicado: (2023)

Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience
por: Serpas Higbie, Victoria, et al.
Publicado: (2022)

Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment
por: Song, Yunfeng, et al.
Publicado: (2021)

The clinicopathological characteristics, prognosis and immune microenvironment mapping in MSI-H/MMR-D endometrial carcinomas
por: Guo, Yu-e, et al.
Publicado: (2022)

Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers
por: Lobo, João, et al.
Publicado: (2019)

Delayed adaptive immunity is related to higher MMR vaccine-induced antibody titers in children
por: Strömbeck, Anna, et al.
Publicado: (2016)

Immune Contexture of MMR-Proficient Primary Colorectal Cancer and Matched Liver and Lung Metastases
por: Ahtiainen, Maarit, et al.
Publicado: (2021)

Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer
por: Inamori, Koji, et al.
Publicado: (2021)

Protective heterologous T cell immunity in COVID-19 induced by MMR and Tdap vaccine antigens
por: Mysore, Vijayashree, et al.
Publicado: (2021)

Alteration in the Immune Microenvironment Based on APC Status in MSS/pMMR Colon Cancer
por: Lin, Haishan, et al.
Publicado: (2022)

Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2022)

BRAF (V600E)/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
por: Colle, Raphael, et al.
Publicado: (2023)

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
por: Liu, Yang, et al.
Publicado: (2018)

Analysis of Immune Landscape Reveals Prognostic Significance of Cytotoxic CD4(+) T Cells in the Central Region of pMMR CRC
por: Qi, Jingwen, et al.
Publicado: (2021)

Resistance to immune checkpoint inhibitors in gastric cancer
por: Liu, Kai, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
por: Huang, Jin-Tao, et al.
Publicado: (2022)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_438tnsb9khlv14sie1op9n5mfd